Centene Corporation
NYSE:CNCMedical - Healthcare Plans
+$0.67 today
- Market cap
- $33.39B
- Beta
- 1.09
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$13.09
Volume 6.29M
Average 6.16M
CNC Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Centene CorporationNYSE: CNC
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization declines year over year
Q2 FY2026 depreciation & amortization of $300M fell 4.8% year over year, behind the -0.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -6.4% a year.
Context
- Depreciation & amortization amounted to 0.7% of revenue in FY2025, down 0.1 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -4.8% toward the trailing-twelve-month pace of -0.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.28B USD
- Year-over-year change
- +2.7%
- 4-year CAGR
- -3.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.28B | +2.7% |
| FY2024 | 2024-12-31 | 1.24B | -4.0% |
| FY2023 | 2023-12-31 | 1.29B | -16.7% |
| FY2022 | 2022-12-31 | 1.55B | +5.2% |
| FY2021 | 2021-12-31 | 1.48B | — |
Depreciation & Amortization vs competitors
How CNC compares with its peers on the latest reported figures
- CNC's LTM Jun 2026 depreciation & amortization of $1.25B is the 5th highest of the 9 companies compared; the peer median is $1.13B.
- Its year-over-year change of -0.8% is the 4th highest of 9, against a peer median of -2.8%.
- Depreciation & amortization amounts to 0.6% of revenue for CNC, versus a peer median of 0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.52B | -2.4% | +2.9% | 1.1% | |
| LTM Sep 2026 | $4.26B | -0.6% | +8.7% | 0.9% | |
| LTM Sep 2026 | $2.89B | +7.2% | -1.9% | 1.0% | |
| LTM Sep 2026 | $1.49B | -3.2% | -2.6% | 0.7% | |
| LTM Jun 2026 | $1.25B | -0.8% | -6.4% | 0.6% | |
| LTM Sep 2026 | $763M | -12.3% | -0.8% | 0.5% | |
| LTM Sep 2026 | $161M | -19.1% | +3.5% | 0.4% | |
| LTM Mar 2026 | $30.69M | +7.1% | +20.4% | 0.7% | |
| LTM Jun 2026 | $28.24M | -7.2% | +23.6% | 0.2% | |
| Peer median (excluding CNC) | $1.13B | -2.8% | +3.2% | 0.7% | |
Competitors are the stored peer set for CNC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 125.98B | 144.55B | 154B | 163.07B | 194.78B |
| Cost of Revenue | 111.78B | 127.89B | 136.68B | 146.24B | 170.94B |
| Gross Profit | 14.2B | 16.66B | 17.32B | 16.83B | 23.83B |
| Gross Margin | 11.3% | 11.5% | 11.2% | 10.3% | 12.2% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 9.6B | 11.59B | 12.56B | 12.4B | 13.26B |
| Operating Expenses | 12.42B | 15.34B | 14.39B | 13.65B | 31.45B |
| Depreciation & Amortization | 1.48B | 1.55B | 1.29B | 1.24B | 1.28B |
| EBITDA | 3.95B | 4.18B | 5.62B | 6.2B | (5.14B) |
| EBITDA Margin | 3.1% | 2.9% | 3.6% | 3.8% | -2.6% |
| Operating Income | 1.78B | 1.32B | 2.93B | 3.18B | (7.62B) |
| Operating Margin | 1.4% | 0.9% | 1.9% | 1.9% | -3.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 665M | 665M | 725M | 702M | 678M |
| Other Income / Expenses | 29M | 644M | 668M | 1.08B | 890.41M |
| Income Before Tax | 1.81B | 1.96B | 3.6B | 4.26B | (6.73B) |
| Pre-Tax Margin | 1.4% | 1.4% | 2.3% | 2.6% | -3.5% |
| Income Tax Expense | 477M | 760M | 899M | 963M | (50.96M) |
| Net Income | 1.35B | 1.2B | 2.7B | 3.31B | (6.67B) |
| Net Margin | 1.1% | 0.8% | 1.8% | 2.0% | -3.4% |
| EPS (Basic) | 2.31 | 2.09 | 4.97 | 6.33 | (13.61) |
| EPS (Diluted) | 2.28 | 2.07 | 4.95 | 6.31 | (13.62) |
| Weighted Avg Shares | 582.83M | 575.19M | 543.32M | 521.79M | 491.07M |
| Weighted Avg Shares (Diluted) | 590.52M | 582.04M | 545.7M | 523.74M | 491.07M |
Centene Corporation
NYSE:CNC
Intrinsic Alpha fair value
Locked
Current Price
$67.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.